Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022)

Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022)

  • Published: March 2016
  • ID: SMRC15595

According to Stratistics MRC, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.

North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.

Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.

Type of Treatments Covered:
• Intraocular Steroid Injection
• Vitrectomy
• Anti-Vascular Endothelial Growth Factor (VEGF) drug
• Laser Surgery

Disease Type Covered:
• Proliferative Diabetic Retinopathy (PDR)
• Non-Proliferative Diabetic Retinopathy (NPDR)
o Moderate
o Mild
o Severe

End Users Covered:
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Hospitals
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain
o Rest of Europe      
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific    
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary       
         
2 Preface 
       
 2.1 Abstract       
 2.2 Stake Holders      
 2.3 Research Scope      
 2.4 Research Methodology      
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources    
  2.5.2 Secondary Research Sources    
  2.5.3 Assumptions     
         
3 Market Trend Analysis      
 3.1 Introduction      
 3.2 Drivers       
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats       
 3.6 End User Analysis      
 3.7 Emerging Markets      
         
4 Porters Five Force Analysis   
   
 4.1 Bargaining power of suppliers     
 4.2 Bargaining power of buyers     
 4.3 Threat of substitutes     
 4.4 Threat of new entrants     
 4.5 Competitive rivalry      
         
5 Global Diabetic Retinopathy Treatment Market, By Treatment type  
 5.1 Introduction       
 5.2 Intraocular Steroid Injection     
 5.3 Vitrectomy      
 5.4 Anti-Vascular Endothelial Growth Factor (VEGF) drug  
 5.5 Laser Surgery      
         
6 Global Diabetic Retinopathy Treatment Market, By Disease Type  
 6.1 Introduction       
 6.2 Proliferative Diabetic Retinopathy (PDR)    
 6.3 Non-Proliferative Diabetic Retinopathy (NPDR)   
  6.3.1 Moderate     
  6.3.2 Mild      
  6.3.3 Severe      
         
7 Global Diabetic Retinopathy Treatment Market, By End User   
 7.1 Introduction       
 7.2 Ophthalmic Clinics      
 7.3 Ambulatory Surgical Centers     
 7.4 Hospitals       
 7.5 Other End Users      
         
8 Global Diabetic Retinopathy Treatment Market, By Geography  
 8.1 North America      
  8.1.1 US      
  8.1.2 Canada      
  8.1.3 Mexico      
 8.2 Europe       
  8.2.1 Germany      
  8.2.2 France      
  8.2.3 Italy      
  8.2.4 UK      
  8.2.5 Spain      
  8.2.6 Rest of Europe     
 8.3 Asia Pacific      
  8.3.1 Japan      
  8.3.2 China      
  8.3.3 India      
  8.3.4 Australia      
  8.3.5 New Zealand     
  8.3.6 Rest of Asia Pacific     
 8.4 Rest of the World      
  8.4.1 Middle East     
  8.4.2 Brazil      
  8.4.3 Argentina     
  8.4.4 South Africa     
  8.4.5 Egypt      
         
9 Key Developments       
 9.1 Agreements, Partnerships, Collaborations and Joint Ventures  
 9.2 Acquisitions & Mergers     
 9.3 New Product Launch     
 9.4 Expansions      
 9.5 Other Key Strategies     
         
10 Company Profiling       
 10.1 Regeneron Pharmaceuticals Inc.    
 10.2 ThromboGenics      
 10.3 Genentech      
 10.4 Bayer Healthcare      
 10.5 Alimera Sciences      
 10.6 Actavis PLC      
 10.7 BCN Peptides      
 10.8 Novartis AG      
 10.9 Ampio Pharmaceuticals     
 10.10 Kowa Group      
 10.11 Sirnaomics Incorporation     
 10.12 Abbott Laboratories Ltd     
 10.13 Glycadia Pharmaceuticals     
 10.14 Alcon Laboratories Inc.     
 10.15 Parexel International Corp.  


List of Tables        

1 Global Diabetic Retinopathy Treatment Market Outlook, By Region (2013-2022) ($MN)
2 Global Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) ($MN)
3 Global Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) ($MN)
4 Global Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) ($MN)
5 Global Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) ($MN)
6 Global Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) ($MN)
7 Global Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) ($MN)
8 Global Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) ($MN)
9 Global Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) ($MN)
10 Global Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) ($MN)
11 Global Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) ($MN)
12 Global Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) ($MN)
13 Global Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) ($MN)
14 Global Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) ($MN)
15 Global Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) ($MN)
16 Global Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) ($MN)
17 Global Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) ($MN)
18 North America Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) ($MN)
19 North America Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) ($MN)
20 North America Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) ($MN)
21 North America Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) ($MN)
22 North America Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) ($MN)
23 North America Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) ($MN)
24 North America Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) ($MN)
25 North America Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) ($MN)
26 North America Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) ($MN)
27 North America Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) ($MN)
28 North America Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) ($MN)
29 North America Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) ($MN)
30 North America Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) ($MN)
31 North America Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) ($MN)
32 North America Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) ($MN)
33 North America Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) ($MN)
34 Europe Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) ($MN)
35 Europe Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) ($MN)
36 Europe Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) ($MN)
37 Europe Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) ($MN)
38 Europe Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) ($MN)
39 Europe Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) ($MN)
40 Europe Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) ($MN)
41 Europe Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) ($MN)
42 Europe Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) ($MN)
43 Europe Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) ($MN)
44 Europe Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) ($MN)
45 Europe Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) ($MN)
46 Europe Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) ($MN)
47 Europe Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) ($MN)
48 Europe Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) ($MN)
49 Europe Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) ($MN)
50 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) ($MN)
51 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) ($MN)
52 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) ($MN)
53 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) ($MN)
54 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) ($MN)
55 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) ($MN)
56 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) ($MN)
57 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) ($MN)
58 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) ($MN)
59 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) ($MN)
60 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) ($MN)
61 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) ($MN)
62 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) ($MN)
63 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) ($MN)
64 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) ($MN)
65 Asia Pacific Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) ($MN)
66 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Treatment type (2013-2022) ($MN)
67 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Intraocular Steroid Injection (2013-2022) ($MN)
68 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Vitrectomy (2013-2022) ($MN)
69 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Anti-Vascular Endothelial Growth Factor (VEGF) drug (2013-2022) ($MN)
70 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Laser Surgery (2013-2022) ($MN)
71 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Disease Type (2013-2022) ($MN)
72 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Proliferative Diabetic Retinopathy (PDR) (2013-2022) ($MN)
73 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Non-Proliferative Diabetic Retinopathy (NPDR) (2013-2022) ($MN)
74 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Moderate (2013-2022) ($MN)
75 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Mild (2013-2022) ($MN)
76 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Severe (2013-2022) ($MN)
77 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By End User (2013-2022) ($MN)
78 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Ophthalmic Clinics (2013-2022) ($MN)
79 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Ambulatory Surgical Centers (2013-2022) ($MN)
80 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Hospitals (2013-2022) ($MN)
81 Rest of the World Diabetic Retinopathy Treatment Market Outlook, By Other End Users (2013-2022) ($MN)

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials